Moreover, sTRAIL-armed MSCs also remodeled the tumor microenvironment and triggered PD-L1 upregulation in the tumor to enhance the therapeutic efficacy of anti-PD-L1 immunotherapy. Here, CD274 is linked to neoplasm.